THE ARISING · Markets & Strategy
Alnylam's Huntington's Drug Cuts Mutant Protein About 60% in Early Study
Alnylam Pharmaceuticals says its experimental Huntington's drug lowered the disease-driving protein by roughly 60% in a small early study, a result STAT says suggests the drug can partially silence the mutant gene. The result puts the company in a crowded race to treat a fatal neurological disorder. This is a company-reported finding from a conference presentation, not a peer-reviewed result.
This article is based on STAT's report of the study. The paper itself was not reviewed, and the figures below have not been checked against it.
According to STAT's report, the drug is called brezosiran. It is a gene-silencing therapy that, the results suggest, partially silences the mutant gene behind Huntington's disease. Patients who received the highest dose saw mutant huntingtin in their spinal fluid fall by 60% or 64% on average, depending on the type of assay used, STAT reported.
Alnylam described the safety profile as "encouraging," according to STAT. Pushkal Garg, the company's head of research and development, told STAT: "We're getting high levels of knockdown with good safety and tolerability, and so this is all very, very encouraging." The company presented the data on Oct. 23 at the European Huntington's Disease Network Clinical Research Congress.
The key limit is what the study did not show. STAT reports that Alnylam plans a placebo-controlled study to prove the drug can actually slow the disease, which implies that has not yet been shown. Lowering a protein in spinal fluid is a biological marker, not proof that patients do better. STAT's visible text did not give the number of patients enrolled. This is the weakest point in the case: a small, early, companyreported study cannot tell us whether patients benefit.
For strategy watchers, the next step is where the value will be decided. Alnylam told STAT it plans to start a placebo-controlled study next year to test whether the drug slows Huntington's. A positive result there would matter far more to its competitive position than any protein reading. A negative one would weigh on the idea that lowering the protein is enough. That is our inference, not a claim from STAT.
STAT describes brezosiran as the latest in a series of intriguing candidates for the disease. That framing suggests a field with several programs chasing the same target. The visible text did not detail the rivals or compare their data, so any ranking of Alnylam against them would be speculation at this stage.
This is an experimental drug.
What to watch next
The design, size and timing of Alnylam's placebo-controlled study planned for next year, and whether it measures real clinical change in patients rather than protein levels alone.
Same Immune Effort, More Survivors: Why Uneven Contact With Target Cells Could Matter AI-Designed Lung Fibrosis Drug Enters Phase III on Small Early Data Could Stiffening Gut Tissue Block Protective Antibodies as We Age? A Long-Shot Idea, Rated 25 Percent Could Methionine Restriction Backfire on the Liver After Menopause? A Testable Idea About Choline, Rated 60 Percent